# A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD)

> **NCT04184882** · PHASE1 · TERMINATED · sponsor: **Astellas Pharma Inc** · enrollment: 8 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy (DMD)

## Interventions

- **DRUG:** Bocidelpar
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04184882
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-24
- **Primary completion:** 2022-09-04
- **Final completion:** 2022-09-04
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Operational Reasons
- **Last updated:** 2024-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04184882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04184882, "A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04184882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*